Radiation Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Department of Radiation Oncology, The Netherlands Cancer Institute (NKI-AVL), Amsterdam, The Netherlands.
Pract Radiat Oncol. 2024 Nov-Dec;14(6):522-540. doi: 10.1016/j.prro.2024.06.006. Epub 2024 Jul 15.
To provide a comprehensive review of the means by which to optimize target volume definition for the purposes of treatment planning for patients with intact prostate cancer with a specific emphasis on focal boost volume definition.
Here we conduct a narrative review of the available literature summarizing the current state of knowledge on optimizing target volume definition for the treatment of localized prostate cancer.
Historically, the treatment of prostate cancer included a uniform prescription dose administered to the entire prostate with or without coverage of all or part of the seminal vesicles. The development of prostate magnetic resonance imaging (MRI) and positron emission tomography (PET) using prostate-specific radiotracers has ushered in an era in which radiation oncologists are able to localize and focally dose-escalate high-risk volumes in the prostate gland. Recent phase 3 data has demonstrated that incorporating focal dose escalation to high-risk subvolumes of the prostate improves biochemical control without significantly increasing toxicity. Still, several fundamental questions remain regarding the optimal target volume definition and prescription strategy to implement this technique. Given the remaining uncertainty, a knowledge of the pathological correlates of radiographic findings and the anatomic patterns of tumor spread may help inform clinical judgement for the definition of clinical target volumes.
Advanced imaging has the ability to improve outcomes for patients with prostate cancer in multiple ways, including by enabling focal dose escalation to high-risk subvolumes. However, many questions remain regarding the optimal target volume definition and prescription strategy to implement this practice, and key knowledge gaps remain. A detailed understanding of the pathological correlates of radiographic findings and the patterns of local tumor spread may help inform clinical judgement for target volume definition given the current state of uncertainty.
全面回顾优化前列腺癌患者靶区定义的方法,重点介绍局灶性加量靶区定义。
本文对现有文献进行综述,总结了目前关于优化局限性前列腺癌治疗靶区定义的知识现状。
历史上,前列腺癌的治疗包括对整个前列腺给予统一的处方剂量,无论是否包括整个或部分精囊。前列腺特异性放射性示踪剂的前列腺磁共振成像(MRI)和正电子发射断层扫描(PET)的发展,开创了放射肿瘤学家能够对前列腺的局部和局灶性剂量递增高危区域进行定位的时代。最近的 3 期数据表明,将局灶性剂量递增至前列腺的高危亚体积可改善生化控制,而不会显著增加毒性。然而,关于最佳靶区定义和实施该技术的处方策略,仍有几个基本问题存在。考虑到存在的不确定性,了解影像学表现的病理相关性以及肿瘤扩散的解剖模式,可能有助于为临床靶区的定义提供临床判断。
先进的影像学技术有能力通过多种方式改善前列腺癌患者的治疗效果,包括对高危亚体积进行局灶性剂量递增。然而,关于最佳靶区定义和实施该技术的处方策略仍有许多问题需要解决,而且关键的知识差距仍然存在。鉴于目前的不确定性,详细了解影像学表现的病理相关性以及局部肿瘤扩散的模式,可能有助于为靶区定义提供临床判断。